Challenge escalated two months after scope confirmation petition
Invalidation could bring launch forward by up to four years
Bioepis leads on first generic exclusivity; path to a final ruling remains uncertain

Celltrion and Samsung Bioepis have each filed petitions seeking to invalidate patents on the formulation of Merck’s (MSD’s) immuno-oncology drug Keytruda (generic name: pembrolizumab). After filing petitions in August seeking rulings that their products do not fall within the scope of the patents, the companies have stepped up their challenge by seeking to invalidate the patents themselves. If the patents are invalidated, the launch of biosimilars in South Korea could be brought forward by up to four years, from 2032 to 2028.

[Exclusive] Celltrion, Samsung Bioepis File Petitions to Invalidate Keytruda Patent View original image

According to industry sources on the 28th, Celltrion and Samsung Bioepis filed petitions with the Intellectual Property Trial and Appeal Board seeking to invalidate some claims of the Keytruda formulation patents, in late September and early October, respectively. In August, the two companies filed petitions seeking rulings that their products did not fall within the scope of the same patents. Just two months later, they added petitions challenging the validity of the patents themselves. Keytruda’s substance patent in South Korea expires in June 2028, but the formulation patents, which protect the combination of additives used with the antibody, remain in effect until March 2032.


If their claims are accepted, both companies could enter the South Korean market in 2028, when the substance patent expires. Keytruda was a blockbuster drug that ranked first worldwide in sales last year, with global revenue of about $31.7 billion (approximately 46 trillion won). It also generated about 548.1 billion won in South Korea over the same period, ranking first in sales among individual products. Even based solely on domestic sales, a market worth more than 2 trillion won would open up over four years. The companies are also seeking to secure time to enter the market before the shift to subcutaneous (SC) formulations takes hold, countering MSD’s strategy to protect sales by switching to an SC formulation.


The outcome of these invalidation trials could also affect the race to launch the first biosimilar in South Korea. Samsung Bioepis is currently in a favorable position to secure preferential sales rights, having been the first in the country to complete both its marketing authorization application and its petition seeking a ruling on patent scope. Preferential sales rights are granted to a follow-on drugmaker that is first to apply for approval and obtains a favorable outcome in a patent trial. In principle, they allow the holder to block sales of other follow-on drugs for nine months from the date sales become possible.


The sales restriction is also tied to the outcome of the current invalidation trials. Under the current Pharmaceutical Affairs Act, if a listed patent is conclusively invalidated and ceases to be in force, the sales restriction attached to preferential sales rights also lapses. An exception applies, however, when the patent is invalidated in a trial petitioned directly by the company that holds the preferential sales rights. This means that if the patent is conclusively invalidated in the trial petitioned by Celltrion, Samsung Bioepis could lose its nine-month exclusivity even if it obtains preferential sales rights. Celltrion filed its petition about 10 days earlier, but the timing of a final decision could differ if the two cases are heard together or if MSD appeals. Depending on the trial outcomes and the process for finalizing them, the initial competitive landscape for Keytruda biosimilars in South Korea could change.



"Since the companies are challenging the patents on two fronts, through invalidation and non-infringement claims, a favorable outcome on either front would significantly increase the chances of entering the South Korean market in 2028," an industry source said. "However, if MSD challenges the rulings and the dispute continues through the Patent Court and the Supreme Court, it could take longer to reach a final decision."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing